Observational Studies Versus Randomized Controlled Trials: Avenues to Causal Inference in Nephrology

Advances in Chronic Kidney Disease

Volumn 19, Issue 1, 2012, Pages 11-18

  Kovesdy, Csaba P ^a,b,c,d   Kalantar Zadeh, Kamyar ^a,b,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Causal inference; Observational studies; Randomized controlled trials

Indexed keywords

SEVELAMER; VITAMIN D;

CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; FINANCIAL MANAGEMENT; FOLLOW UP; HUMAN; KIDNEY FAILURE; LIFESTYLE; LUNG CANCER; NEPHROLOGY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RICKETS; SMOKING; SUN EXPOSURE; ULTRAVIOLET RADIATION;

EVIDENCE-BASED MEDICINE; HUMANS; NEPHROLOGY; OBSERVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857397981     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.09.004     Document Type: Review

References (38)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, 76:S1-S130.
2. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
3. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
4. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
5. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
6. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
7. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
8. Suki W.N., Zabaneh R., Cangiano J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007, 72:1130-1137.
9. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298:1163-1170.
10. Sniadecki J. In: Dziela. Warsaw, Poland; 1840:273-274.
11. Brater D.C., Daly W.J. Clinical pharmacology in the middle ages: principles that presage the 21st century. Clin Pharmacol Ther 2000, 67:447-450.
12. Kalantar-Zadeh K., Navab M. The importance of origins?. Science 2005, 309:1673-1675.
13. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 1965, 58:295-300.
14. Shinaberger C.S., Kopple J.D., Kovesdy C.P., et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008, 3:1769-1776.
15. Mark S.D., Robins J.M. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Control Clin Trials 1993, 14:79-97.
16. Palmer S.C., McGregor D.O., Macaskill P., Craig J.C., Elder G.J., Strippoli G.F. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007, 147:840-853.
17. Coyne D.W. Vitamin D compounds in chronic kidney disease. Ann Intern Med 2008, 148:969-970.
18. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:S1-S290.
19. Palmer B.F. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002, 347:1256-1261.
20. Kalantar-Zadeh K., Kilpatrick R.D., McAllister C.J., Greenland S., Kopple J.D. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th Annual Fall Conference and Scientific Sessions. Hypertension 2005, 45:811-817.
21. Kovesdy C.P., Trivedi B.K., Kalantar-Zadeh K., Anderson J.E. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 2006, 21:1257-1262.
22. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
23. Cooper B.A., Branley P., Bulfone L., et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010, 363:609-619.
24. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70:771-780.
25. Melamed M.L., Eustace J.A., Plantinga L., et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006, 70:351-357.
26. Naves-Diaz M., Alvarez-Hernandez D., Passlick-Deetjen J., et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008, 74:1070-1078.
27. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006, 70:1858-1865.
28. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008, 168:397-403.
29. Robins J.M., Hernan M.A., Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11:550-560.
30. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115-1125.
31. Tentori F., Albert J.M., Young E.W., et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009, 24:963-972.
32. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349:446-456.
33. Glymour M.M., Greenland S. Causal diagrams. Modern Epidemiology 2008, 183-209. Lippincott Williams & Wilkins, Philadelphia, PA. 3rd ed. K. Rothman, S. Greenland, T.L. Lash (Eds.).
34. Smith G.D., Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004, 33:30-42.
35. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 359:1897-1908.
36. Kalantar-Zadeh K., Kovesdy C.P. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1529-1539.
37. Streja E., Kovesdy C.P., Greenland S., et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008, 52:727-736.
38. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006, 17:1181-1191.